Strategic question
How does our preferred venture partner compare against credible alternatives in the same market and therapeutic focus?
How Galen Growth helped
From market signal to decision-ready evidence
Using HealthTech Alpha’s Alpha Score and Similarity Index, we identified comparable ventures across the US and China, then built a defensible comparative benchmark against the client’s preferred partner.
Outcomes
Re-anchored the partnership decision in comparative evidence rather than single-venture due diligence.
Decision enabled: Enabled the investment committee to confirm, or challenge, the preferred partnership on a defensible basis.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Sourcing OMICS Ventures to Shape Oncology and Wellness Strategy
Which OMICS-led ventures tackling oncology and wellness are mature enough to partner with an enterprise insurer?
Sourcing HealthTech Ventures to Power Non-Fluid Underwriting
Which ventures across digital biomarkers, DTx, genomics and teleconsultation are mature enough to enable non-fluid underwriting?
Helping an APAC Insurer Prioritise Markets, Categories and Venture Targets
Which APAC markets, therapeutic areas and Digital Health categories should we prioritise to accelerate regional growth?